LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.01 USD | -7.66% |
|
-3.38% | -33.51% |
| Jun. 01 | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
| May. 31 | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,735 | 7,175 | 8,357 | 10,938 | 7,293 | - | - |
| Enterprise Value (EV) 1 | 3,233 | 6,446 | 7,855 | 9,959 | 6,533 | 6,497 | 6,255 |
| P/E ratio | -22 x | -34 x | -35.7 x | -40.9 x | -39.3 x | -77.2 x | 109 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 49.4 x | 79.9 x | 71.4 x | 38.4 x | 13.9 x | 7.04 x | 4.67 x |
| EV / Revenue | 42.7 x | 71.8 x | 67.1 x | 34.9 x | 12.5 x | 6.28 x | 4.01 x |
| EV / EBITDA | -14.6 x | -17.9 x | -17.7 x | -25.4 x | -18.2 x | -48 x | 42.2 x |
| EV / FCF | -12 x | -26.6 x | -33.1 x | -24.1 x | -9.35 x | -91.3 x | 28.7 x |
| FCF Yield | -8.31% | -3.76% | -3.02% | -4.15% | -10.7% | -1.1% | 3.48% |
| Price to Book | 26.7 x | 30.5 x | - | 17.5 x | 10.5 x | 6.95 x | 4.88 x |
| Nbr of stocks (in thousands) | 132,638 | 153,946 | 167,403 | 181,789 | 182,283 | - | - |
| Reference price 2 | 28.16 | 46.61 | 49.92 | 60.17 | 40.01 | 40.01 | 40.01 |
| Announcement Date | 3/18/21 | 3/18/22 | 3/30/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 75.68 | 89.79 | 117 | 285.1 | 523.1 | 1,035 | 1,560 |
| EBITDA 1 | -220.8 | -360.6 | -443.2 | -392.1 | -358.2 | -135.4 | 148.4 |
| EBIT 1 | -229.2 | -373 | -455.8 | -412.6 | -391.1 | -163.1 | 161 |
| Operating Margin | -302.87% | -415.44% | -389.58% | -144.69% | -74.76% | -15.76% | 10.32% |
| Earnings before Tax (EBT) 1 | -307.6 | -386.2 | -445.7 | -520.1 | -346.4 | -160.1 | 157.4 |
| Net income 1 | -303.5 | -386.2 | -446.3 | -518.3 | -342.9 | -153.1 | 140.1 |
| Net margin | -401.02% | -430.12% | -381.48% | -181.75% | -65.55% | -14.79% | 8.98% |
| EPS 2 | -1.280 | -1.370 | -1.400 | -1.470 | -1.017 | -0.5185 | 0.3682 |
| Free Cash Flow 1 | -268.8 | -242.4 | -237 | -413.4 | -699 | -71.18 | 217.9 |
| FCF margin | -355.14% | -269.92% | -202.57% | -144.97% | -133.63% | -6.87% | 13.96% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 146.86% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 155.52% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/18/21 | 3/18/22 | 3/30/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 39 | 40.83 | 11.97 | 36.34 | 73.33 | 96.01 | 79.46 | 93.99 | 118.7 | 134.4 | 179.1 | 188.8 | 241.8 |
| EBITDA 1 | -114.2 | - | -116.1 | - | - | -53.64 | - | -48.59 | -109 | -101.2 | -102.3 | -56.7 | -56.73 |
| EBIT 1 | -117.5 | -76 | -125.5 | -106.9 | -104.3 | -56.82 | -141 | -54.31 | -94.94 | -104.1 | -93.55 | -76.03 | -36.47 |
| Operating Margin | -301.22% | -186.16% | -1,048.6% | -294.09% | -142.25% | -59.18% | -177.43% | -57.79% | -79.96% | -77.47% | -52.24% | -40.27% | -15.08% |
| Earnings before Tax (EBT) 1 | -88.33 | -41.09 | -193.1 | -112 | -198.8 | -62.5 | -146.8 | -59.79 | -91.3 | -102.3 | -90.89 | -74.49 | -35.17 |
| Net income 1 | -88.33 | -41.09 | -193.2 | -112.1 | -199.1 | -62.21 | -144.8 | -59.79 | -94.02 | -103.4 | -93.66 | -74.56 | -35.26 |
| Net margin | -226.53% | -100.64% | -1,614.13% | -308.51% | -271.55% | -64.79% | -182.24% | -63.62% | -79.18% | -76.92% | -52.3% | -39.49% | -14.58% |
| EPS 2 | -0.3000 | -0.1300 | -0.6200 | -0.3400 | -0.5700 | -0.1700 | -0.4000 | -0.1600 | -0.2689 | -0.3051 | -0.2806 | -0.2060 | -0.1120 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/18/22 | 6/1/22 | 2/17/23 | 5/18/23 | 8/15/23 | 11/20/23 | 3/11/24 | 5/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 502 | 729 | 501 | 979 | 760 | 796 | 1,038 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -269 | -242 | -237 | -413 | -699 | -71.2 | 218 |
| ROE (net income / shareholders' equity) | -284% | -103% | -59.1% | -51.9% | -34.1% | -17.4% | 13.6% |
| ROA (Net income/ Total Assets) | -44.3% | -42% | -36.4% | -32.6% | -24.2% | -17.8% | 8.4% |
| Assets 1 | 684.9 | 919.7 | 1,225 | 1,590 | 1,417 | 858.8 | 1,667 |
| Book Value Per Share 2 | 1.050 | 1.530 | - | 3.440 | 3.810 | 5.760 | 8.200 |
| Cash Flow per Share 2 | - | - | - | - | -0.9000 | -0.8100 | 0.1800 |
| Capex 1 | 45.7 | 43.9 | 35.7 | 20.1 | 51.4 | 37.4 | 38 |
| Capex / Sales | 60.45% | 48.9% | 30.54% | 7.04% | 9.82% | 3.61% | 2.44% |
| Announcement Date | 3/18/21 | 3/18/22 | 3/30/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
40.01
USD
Average target price
83.03
USD
Spread / Average Target
+107.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.51% | 7.29B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- LEGN Stock
- Financials Legend Biotech Corporation
